Denali Therapeutics (DNLI) Earnings Beat Puts Valuation Back In Focus
Denali Therapeutics (DNLI) released third quarter 2026 results that swung to a profit and were driven by stronger than expected AVLAYAH sales, alongside fresh revenue guidance for the fourth quarter. Scan beyond Denali Therapeutics and evaluate other potential opportunities in rare…